AbbVie: H1 2025 Earnings Strengthen Case For Targeting Gilgamesh Acquisition

AbbVie Inc. (NYSE: ABBV ) released Q2 2025 earnings confirming the extraordinary performance of Skyrizi and Rinvoq, which accounted for $6.4 billion in global sales, 41% of AbbVie’s total revenues for Q2. More importantly, both products are demonstrating theirOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineering, with +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs. As an investor, I have been utilising my background in l ...